首页 / 院系成果 / 成果详情页

US-guided Percutaneous Radiofrequency Ablation for Secondary Hyperparathyroidism: Long-term Outcomes and Prognostic Factors 期刊论文

编号：

54A93EF9EC40408DDA089984CB8F1143
作者：

Yue, Wenwen(岳雯雯)^[1,2]Jiang, Tingting^[1,2];Ai, Zisheng(艾自胜)^[3]Deng, Erya^[1,2];Chai, Huihui^[1,2];Li, Xiaolong(李小龙)^[4]He, Hongfeng(何洪峰)^[5]Zhang, Zhengxian^[6];Weng, Ning^[7];Qin, Xiachuan(覃夏川)^[8,9]Fan, Jing^[10];Tang, Xiaoqing^[10];Heng, Wei^[11];Li, Yong^[12];Sun, Liping(孙丽萍)^[1,2]Peng, Chengzhong(彭成忠)^[1,2]Xu, Huixiong(徐辉雄)^[4]
语种：

英文
期刊：

RADIOLOGY ISSN：0033-8419 2024 年 311 卷 1 期 ; APR
收录：
摘要：

Background: Although favorable outcomes have been reported with radiofrequency ablation (RFA) for secondary hyperparathyroidism (SHPT), the long-term efficacy remains insufficiently investigated. Purpose: To evaluate the long-term efficacy and safety of US -guided percutaneous RFA in patients with SHPT undergoing dialysis and to identify possible predictors associated with treatment failure. Materials and Methods: This retrospective study included consecutive patients with SHPT with at least one enlarged parathyroid gland accessible for RFA who were undergoing dialysis at seven tertiary centers from May 2013 to July 2022. The primary end point was the proportion of patients with parathyroid hormone (PTH) levels less than or equal to 585 pg/mL at the end of follow-up. Secondary end points were the proportion of patients with normal calcium and phosphorus levels, the technical success rate, procedure -related complications, and improvement in self -rated hyperparathyroidism-related symptoms (0-3 ranking scale). The Wilcoxon signed rank test and generalized estimating equation model were used to evaluate treatment outcomes. Univariable and multivariable regression analyses identified variables associated with treatment failure (recurrent or persistent hyperparathyroidism). Results: This study included 165 patients (median age, 51 years [IQR, 44-60 years]; 92 female) and 582 glands. RFA effectively reduced PTH, calcium, and phosphorus levels, with targeted ranges achieved in 78.2% (129 of 165), 72.7% (120 of 165), and 60.0% (99 of 165) of patients, respectively, at the end of follow-up (mean, 51 months). For the RFA sessions, the technical success rate was 100% (214 of 214). Median symptom scores (ostealgia, arthralgia, pruritus) decreased (all P < .001). Regarding complications, only hypocalcemia (45.8%, 98 of 214) was common. Treatment failure occurred in 36 patients (recurrent [ n = 5] or persistent [ n = 31] hyperparathyroidism). The only potential independent predictor of treatment failure was having less than four treated glands (odds ratio, 17.18; 95% CI: 4.34, 67.95; P < .001). Conclusion: US -guided percutaneous RFA was effective and safe in the long term as a nonsurgical alternative for patients with SHPT undergoing dialysis; the only potential independent predictor of treatment failure was a lower number (<4) of treated glands. (c) RSNA, 2024
推荐引用方式
GB/T 7714：

Yue Wenwen,Jiang Tingting,Ai Zisheng, et al. US-guided Percutaneous Radiofrequency Ablation for Secondary Hyperparathyroidism: Long-term Outcomes and Prognostic Factors [J].RADIOLOGY,2024,311(1).
APA：

Yue Wenwen,Jiang Tingting,Ai Zisheng,Deng Erya,&Xu Huixiong.(2024).US-guided Percutaneous Radiofrequency Ablation for Secondary Hyperparathyroidism: Long-term Outcomes and Prognostic Factors .RADIOLOGY,311(1).
MLA：

Yue Wenwen, et al. "US-guided Percutaneous Radiofrequency Ablation for Secondary Hyperparathyroidism: Long-term Outcomes and Prognostic Factors" .RADIOLOGY 311,1(2024).
入库时间：

2025/2/19 13:08:30
更新时间：

2025/2/21 12:42:40

浏览次数：4  下载次数：0

分享到：

浏览次数：4

下载次数：0

打印次数：0